Physician profile
Stuart A Issleib
NPI 1497740393
$1,959.50
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $538 · 2021: $734 · 2022: $178 · 2023: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $762.35 | 2019-2023 | Xifaxan, Plenvu, Trulance |
| Braintree Laboratories, INC. | $384.17 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.48 | 2019-2020 | |
| Redhill Biopharma INC. | $147.96 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.36 | 2021 | |
| Shionogi INC | $98.54 | 2020 | |
| Celgene Corporation | $93.51 | 2021-2023 | Zeposia |
| Abbvie INC. | $73.37 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $34.77 | 2020 | |
| Merck Sharp & Dohme LLC | $30.72 | 2023 | Dificid |
| Alfasigma USA, INC. | $27.05 | 2020 | |
| Boston Scientific Corporation | $15.11 | 2023 | Advantage System |
| Allergan, INC. | $13.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Issleib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.